Erosion of the principal investigator role in a climate of industry dominance

European Journal of Cancer

Volumn 41, Issue 15, 2005, Pages 2206-2209

  Rowinsky, Eric K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Drug development; Pharma industry

Indexed keywords

ANTINEOPLASTIC AGENT;

BIOTECHNOLOGICAL PRODUCTION; CANCER RESEARCH; CLINICAL RESEARCH; DRUG APPROVAL; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; PATENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 26244468058     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.07.010     Document Type: Article

References (7)

1. M.M. Mello, B.R. Clarridge, and D.M. Studdert Academic medical centers' standards for clinical trial agreements with industry N Engl J Med 352 2005 2202 2210
2. E.J. Topol Failing the public health - rofecoxib, Merck and the FDA N Engl J Med 347 2004 1362 1363
3. D.G. Nathan, and D.J. Weatherall Academic freedom in clinical research N Engl J Med 347 2002 1368 1371
4. H. Moses III, E. Braunwald, and J.B. Martin Collaborating with industry - choices for the academic medical center N Engl J Med 347 2002 1371 1375
5. D. Blumenthal Academic-industry relationships in the life sciences: extent, consequences, and management JAMA 268 1992 3344 3349
6. A.C. Gelijins, and A.S. Thier Medical innovation and institutional interdependence: rethinking university-industry connections JAMA 287 2002 72 77
7. A.T. Tolcher, C. Takimoto, and E.K. Rowinsky The multi-functional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large" J Clin Oncol 21 2002 4276 4278